SUPN completed a major acquisition of Sage Therapeutics that dramatically increased revenue by 285% but caused the company to swing from profitable to unprofitable operations.
The acquisition of Sage Therapeutics and its zuranolone license represents a transformative deal that fundamentally changed SUPN's business profile, shifting from a profitable specialty pharma to a larger but currently unprofitable entity focused on CNS disorders. The mention of CVRs (contingent value rights) and merger agreement details suggests this was a complex, expensive transaction that investors will need to monitor closely for integration success and return to profitability.
Revenue surged 285% to $393M from the Sage acquisition, but this growth came at a steep cost as the company swung from $74M profit to a $39M loss due to 51% higher SG&A expenses and integration costs. While the balance sheet strengthened with 85% higher cash and doubled inventory levels, operating cash flow collapsed 73% to $47M, indicating significant cash burn from the enlarged operations. The overall picture shows a company that has dramatically expanded through acquisition but now faces the critical challenge of returning to profitable growth while digesting a transformative but expensive deal.
Strong top-line growth of 284.5% — accelerating demand or successful expansion into new markets.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Net income declined 152.2% — review whether driven by operations, interest costs, or non-recurring items.
Inventory surged 107.2% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Cash position surged 85.3% — strong cash generation or capital raise providing significant financial cushion.
Capital expenditure jumped 84.6% — major investment cycle underway; assess returns on deployment.
Operating cash flow fell 72.5% — earnings quality concerns; investigate working capital changes and non-cash items.
SG&A up 51% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Receivables surged 32.2% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Liabilities increased 17.6% — monitor debt-to-equity ratio and interest coverage.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →